**Company Profile**

**Industry Sector:** Research and Development - Medical Devices

**Company Overview:** Potrero Medical is a spin-off of TheraNova, LLC, a biomedical device incubator located in San Francisco, CA, and was incorporated in 2014 to bring medical innovations to the critical care market. Potrero’s technologies will mandate the “Triple Aim”: 1) improve outcomes for patients; 2) reduce healthcare costs; 3) improve access to healthcare.

**Target Markets:** Intensive care units (burn, trauma, other) in hospitals and clinics.

---

**Key Value Drivers**

**Technology:** The Accuryn Monitoring System is a real-time catheter-based system that enables clinicians to monitor the health of critically ill patients by providing a continuous feed of data comprising a unique set of vital parameters, including core body temperature, intra-abdominal pressure and urine output. The system will be able to warn for (early) development of critical illnesses and guide fluid resuscitation.

**Competitive Advantage:** The technology represents a significant improvement over current systems that require manual entry of vital signs, are intermittent in data collection, are restricted to the detection of a limited number of vital signs, or fail to utilize data streams for prevention and possible predictions of life-threatening diseases.

**Plan & Strategy:** We will use predictive data analytics to drive diagnosis and management of critical diseases. We will launch three generation devices to optimize fluid resuscitation (Gen 1), detect and prevent catheter-associated urinary tract infections (Gen 2), and detect and predict the development of multiple critical diseases (Gen 3).

---

**Management**

**Leadership:** Potrero has a full-time staff of over 20 employees, contractors and consultants with a variety of clinical, business, regulatory, engineering and R&D experience. Potrero’s CEO is Dr. Daniel Burnett, a Duke/Mayo Clinic-trained medical doctor, who founded seven venture-backed spin-outs that have raised over $240M in capital.

**Scientific Advisory Board:** Potrero has engaged with renowned US clinicians and scientists in the field of critical care, including Michael Pinsky, MD, University of Pittsburgh; Suchi Saria, PhD, Johns Hopkins University; David Greenhalgh, MD, UC Davis; David Herndon, MD, UTMB; Hobart Harris, MD, UCSF; Phillip Dellinger, MD, Cooper University.

---

**Product Pipeline**

**Gen 1 – Fluid Resuscitation:**
- Continuous monitoring of vital parameters to personalize blood pressure management and guide fluid resuscitation
- EHR integration for wireless data monitoring
- Urimeter with proprietary airlock-prevention technology to overcome urine drainage issues

**Gen 2 – Catheter-Associated Urinary Tract Infections:**
Built-in urine spectroscopy and optimized Gen 1 catheter and cassette design to detect bacteria in the bladder

**Gen 3 – Critical Disease Surveillance:**
Predictive analytics to warn for (early onset) of sepsis and potentially, acute kidney injury and cardiac illness